Featured Research

from universities, journals, and other organizations

Potential treatment for Chikungunya discovered

Date:
February 28, 2011
Source:
Agency for Science, Technology and Research (A*STAR), Singapore
Summary:
Researchers have discovered two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS (NYSE Euronext: VLS), a French biopharmaceutical company, has announced the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

The international team of scientists, coordinated by Dr Lucile Warter of SIgN, has published their groundbreaking discovery in the Journal of Immunology.

Chikungunya is prevalent in Africa, South Asia, and South-East Asia and is transmitted by the Aedes mosquito, the same mosquito that spreads dengue fever. In Singapore alone, over 1000 Chikungunya cases were reported over the period 2008-2010. Dr Warter and her collaborators used Humalex, a VIVALIS technology platform designed to identify and generate fully human monoclonal antibodies, to develop two antibodies that could neutralize several Chikungunya strains in vitro by culturing immune cells from an individual who had developed resistance to Chikungunya. Monoclonal antibodies can be more potent and have fewer side effects than conventional small molecule drugs.

"The discovery of these antibodies is a big step forward in combating a disease that presently has no available vaccine or specific treatment. The use of VIVALIS' Humalex was invaluable in helping us isolate the target antibodies from the cultured immune cells. We hope to further validate the use of these antibodies as a viable treatment for Chikungunya." said Dr Warter. She added that further testing in vivo would have to be carried out to validate the antibodies' performance as a potential treatment for Chikungunya.

"It is thanks to the successful synergy between industry and SIgN that the development of two antibodies against a disease that is on the rise has been accomplished. The combination of Humalexฎ technology, SIgN's expertise in human immunology, virology and molecular biology, and Singapore's location as a hub for Asia helped to speed up the selection, sequencing and characterization of the most potent antibody candidates. I am delighted to note that this breakthrough was achieved in less than a year from the start of the project," said SIgN Chairman Prof Philippe Kourilsky.

"The new platform used by SIgN for the generation of fully human monoclonal antibody is already providing excellent results, and we hope to generate a number of new fully human monoclonal antibodies that could be used as therapeutics," said SIgN Scientific Director Prof. Paola Castagnoli.

"The discovery of these new fully human monoclonal antibodies with strong neutralizing activities against the Chikungunya virus constitutes an an additional testimony of the efficiency of the Humalex platform. Coming shortly after the signature of a major commercial agreement with sanofi Pasteur, the vaccine division of Sanofi Aventis, this discovery is a further validation of the power of VIVALIS Humalex antibody discovery platform. It is a first milestone in our research partnership with SIgN and we expect to benefit from the excellent scientific input from SIgN scientists in the field of immunology in future collaborative programs," commented Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS.


Story Source:

The above story is based on materials provided by Agency for Science, Technology and Research (A*STAR), Singapore. Note: Materials may be edited for content and length.


Journal Reference:

  1. L. Warter, C. Y. Lee, R. Thiagarajan, M. Grandadam, S. Lebecque, R. T. P. Lin, S. Bertin-Maghit, L. F. P. Ng, J.-P. Abastado, P. Despres, C.-I. Wang, A. Nardin. Chikungunya Virus Envelope-Specific Human Monoclonal Antibodies with Broad Neutralization Potency. The Journal of Immunology, 2011; 186 (5): 3258 DOI: 10.4049/jimmunol.1003139

Cite This Page:

Agency for Science, Technology and Research (A*STAR), Singapore. "Potential treatment for Chikungunya discovered." ScienceDaily. ScienceDaily, 28 February 2011. <www.sciencedaily.com/releases/2011/02/110216111935.htm>.
Agency for Science, Technology and Research (A*STAR), Singapore. (2011, February 28). Potential treatment for Chikungunya discovered. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2011/02/110216111935.htm
Agency for Science, Technology and Research (A*STAR), Singapore. "Potential treatment for Chikungunya discovered." ScienceDaily. www.sciencedaily.com/releases/2011/02/110216111935.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) — President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) — A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) — Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) — New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

    Technology News



    Save/Print:
    Share:  

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile iPhone Android Web
    Follow Facebook Twitter Google+
    Subscribe RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins